血小板生成素受体激动剂在血小板减少性疾病中应用的研究进展被引量：3

Research progress on applications of thrombopoietin receptor agonist in thrombocytopenic diseases

导出

摘要血小板减少性疾病是常见的血液系统疾病，病因繁多，多见于原发免疫性血小板减少症（ITP）、骨髓衰竭性疾病、恶性血液病、慢性肝脏疾病，以及化疗引起的血小板减少症。目前，血小板生成素受体激动剂（TPORA）在各种血小板减少性疾病治疗中具有重要意义，可有效提高患者血小板计数，为血小板减少性疾病患者提供新的治疗方法。本文就TPORA在血小板减少性疾病中的临床应用和治疗安全性方面的研究进展进行综述。 Thrombocytopenic diseases are common diseases of the blood system diseases, which have various pathopoiesis factors. This clinical disorder can be found in the following diseases： primary immune thrombocytopenia （ITP）, bone marrow failure diseases, hematologic malignancies, chronic liver disease and thromboeytopenia caused by chemotherapy and so on. Currently thrombopoietin receptor agonists （TPRA） play a significant role in improving the count of platelets effectively. This article reviews the research progress on clinical application and therapeutic safety of TPORA in thrombocytopenic diseases.

作者郭妹沈文怡陆化

机构地区南京医科大学第一附属医院血液科.

出处《国际输血及血液学杂志》 CAS 2016年第1期50-53,共4页 International Journal of Blood Transfusion and Hematology

基金国家自然科学基金项目（81400079）

关键词受体血小板生成素血小板减少贫血再生障碍性血液肿瘤慢性病肝疾病 Receptors, thrombopoietin Thromboeytopenia Anemia, aplastie Hematologic neoplasms Chronic disease Liver diseases

分类号 R558.2 [医药卫生—血液循环系统疾病]

作者简介通信作者：陆化，Email：luhua1956@aliyun．com

引文网络
相关文献

参考文献25

1GeddisAE,LindenHM,KaushanskyK.Thrombopoietin: a pan-hematopoietic cytokine [J].Cytokine Growth Factor Rev,2002,13(1):61-73.DOI: 10.1016/S1359-6101(01)00030-2.
2赵永强,王庆余,翟明,徐健,陈协群,刘文励,张梅,宋善俊,王健民,孟凡义,单渊东.重组人血小板生成素治疗慢性难治性特发性血小板减少性紫癜的多中心临床试验[J].中华内科杂志,2004,43(8):608-610. 被引量：103
3王书杰,杨仁池,邹萍,侯明,吴德沛,沈志祥,卢锡京,李艳,陈协群,牛挺,孙慧,于力,王昭,张茵,常乃柏,张高魁,赵永强.重组人血小板生成素治疗特发性血小板减少性紫癜的多中心随机对照临床试验[J].血栓与止血学,2010,16(4):149-153. 被引量：60
4梁艳,邹晓阳,崔晓,富州.聚乙二醇化重组人巨核细胞生长及发育因子致血小板减少症[J].中国临床药理学杂志,2006,22(2):90-90. 被引量：2
5ChalmersS,TarantinoMD.Romiplostim as a treatment for immune thrombocytopenia: a review [J].J Blood Med,2015,6:37-44.DOI: 10.2147/JBM.S47240.
6KuterDJ,BusselJB,LyonsRM,et al.Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial [J].Lancet,2008,371(9610):395-403.DOI: 10.1016/S0140-6736(08)60203-2.
7KuterDJ,RummelM,BocciaR,et al.Romiplostim or standard of care in patients with immune thrombocytopenia[J].N Engl J Med,2010,363(20):1889-1899.DOI: 10.1056/NEJMoa1002625.
8KantarjianH,FenauxP,SekeresMA,et al.Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thromboeytopenia[J].J Clin Oncol,2010,28(3):437-444.DOI: 10.1200/JCO.2009.24.7999.
9Erickson-MillerCL,DelormeE,TianSS,et al.Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist [J].Stem Cells,2009,27(2):424-430.DOI: 10.1634/stemcells.2008-0366.
10BusselJB,ChengG,SalehMN,et al.Eltrombopag for the treatment of chronic idiopathic thmmbocytopenie purpura[J].N Engl J Med,2007,357(22):2237-2247.DOI: 10.1056/NEJMoa073275.

二级参考文献87

1赵永强,王庆余,翟明,徐健,陈协群,刘文励,张梅,宋善俊,王健民,孟凡义,单渊东.重组人血小板生成素治疗慢性难治性特发性血小板减少性紫癜的多中心临床试验[J].中华内科杂志,2004,43(8):608-610. 被引量：103
2KUTER DJ.Future directions with platelet growth factors[J].Seminar Hemotol,2000,37:41-49.
3CHANG M,NAKAGAWA PA,WILLIAMS SA,et al.Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro[J].Blood,2003,102:887-895.
4WENDLING F,MARASKOVSKY E,DEBILI N,et al.cMpl lig-and is a humoral regulator of megakaryocytopoiesis[J].Nature,1994,369:571-574.
5SABATH DF,KAUSHANSKY K,BROUDY VC.Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding[J].Blood,1999,94:365-367.
6CREMER M,SCHULZE H,LINTHORST G,et al.Serum levels of thrombopoietin,IL-11,and IL-6 in pediatric thrombocytopenias[J].Ann Hematol,1999,78:401-407.
7von dem BORNE A,FOLMAN C,van den OUDENRIJN S,et al.The potential role of thrombopoietin in idiopathic thrombocytopenicpurpura[J].Blood Rev,2002,16,57-59.
8LI J,YANG C,XIA Y,et al.Thrombocytopenia caused by the development of antibodies to thrombopoietin[J].Blood,2001,98:3241-3248.
9BASSER RL,O' FLAHERTY E,GREEN M,et al.Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor[J].Blood,2002,99:2599-2602.
10KUTER DJ.New drugs for familiar therapeutic targets? thrombopoietin receptor agonists and immune thrombocytopenic purpura[J].Eur j Haematol(Suppl),2008,(69):9-18.